dad, I don't think you have it right. You need to go to Cytodyn website and review the PR's. Leronlimab is not a vaccine. It does not necessarily reduce the viral load for new patients. This is being studied, but no one will going to a lab or clinic, getting an injection of leronlimab, and then going home. First of all it requires two weekly injections.
Secondly, and more importantly, Leronlimab is for sick people. It prevents the immune system from producing a "cytokine storm" that overwhelms the immune system and destroys the lungs, heart, and other organs.
If you review the current Phase 2/3 trial, which has just been completed, you'll get a better idea as to how Leronlimab works. Enthusiasm by all fellow investors is appreciated, but investors need to understand their investments; in this case, why is leronlimab a potential treatment for patients with the corona virus?
The next 2-3 weeks should be very exciting to all CYDY longs. Enjoy the rest of the Holiday weekend.
News 
Market Data 
Discover 
